|
注册号: Registration number: |
ChiCTR2600121679 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-01 16:50:25 |
|
注册时间: Date of Registration: |
2026-04-01 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
围产期抑郁症的发病机制及诊疗技术研究 |
|
Public title: |
A study of the pathogenesis and diagnostic, and therapeutic interventions for perinatal depression |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
围产期抑郁症的发病机制及诊疗技术研究 |
|
Scientific title: |
A study of the pathogenesis and diagnostic, and therapeutic interventions for perinatal depression |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘帮杉 |
研究负责人: |
张燕 |
|
Applicant: |
Bangshan Liu |
Study leader: |
Yan Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 151 1108 2510 |
研究负责人电话:
Study leader's |
+86 138 0731 5182 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
bangshan.liu@csu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
yan.zhang@csu.ed.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
研究负责人通讯地址: |
湖南省长沙市芙蓉区人民中路139号 |
|
Applicant address: |
No. 139, Renmin Middle Road, Furong District, Changsha City, Hunan Province |
Study leader's address: |
No. 139, Renmin Middle Road, Furong District, Changsha City, Hunan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
中南大学湘雅二医院 |
||
|
Applicant's institution: |
The Second Xiangya Hospital of Central South University |
||
|
研究负责人所在单位: |
中南大学湘雅二医院 |
||
|
Affiliation of the Leader: |
The Second Xiangya Hospital of Central South University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
(2025)国伦审[科]第(K013)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中南大学湘雅二医院国家临床医学研究中心伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of National Clinical Research Center,The Second Xiangya Hospital of Central South University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-10 00:00:00 | ||
|
伦理委员会联系人: |
颜湘 |
||
|
Contact Name of the ethic committee: |
Xiang Yan |
||
|
伦理委员会联系地址: |
湖南省长沙市芙蓉区人民中路139号 |
||
|
Contact Address of the ethic committee: |
No. 139, Renmin Middle Road, Furong District, Changsha City, Hunan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 731 8529 5391 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
yanxiang@csu.edu.cn |
|
研究实施负责(组长)单位: |
中南大学湘雅二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Xiangya Hospital of Central South University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省长沙市芙蓉区人民中路139号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 139, Renmin Middle Road, Furong District, Changsha City, Hunan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金联合基金项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Project supported by the Joint Funds of the National Natural Science Foundation of China |
||||||||||||||||||||||
|
研究疾病: |
围产期抑郁症 |
||||||||||||||||||||||
|
Target disease: |
perinatal depression |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
在前期已建立的贯穿围产期全程的前瞻性队列基础上,筛选并确定PND的多维度客观诊断标记物和有效干预的治疗新靶标,并进一步扩大队列样本量构建PND的发病、诊断和疗效预测模型。并针对PND患者及高危人群开展在线平台远程实施的CBT,评估该方法在改善孕产妇抑郁和焦虑症状方面的效果,并进一步探索其在我国的实施可行性与接受度。 |
||||||||||||||||||||||
|
Objectives of Study: |
Based on the previously established prospective cohort covering the entire perinatal period, this study will screen and identify multi-dimensional objective diagnostic markers and new therapeutic targets for effective intervention of PND, and further expand the cohort sample size to construct models for predicting the onset, diagnosis and therapeutic efficacy of PND. Additionally, it will implement online remote CBT for PND patients and high-risk groups, evaluate its effectiveness in improving maternal depression and anxiety symptoms, and further explore its feasibility and acceptability in China. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
a) 有精神分裂症、双相情感障碍等现病史或既往史(焦虑障碍谱系不排除); b) 有神经系统疾病史或重大躯体疾病(如甲状腺疾病、红斑狼疮、糖尿病、肺肝肾损害、感染、重大外伤、青光眼等)史;有物质使用障碍; c) 当前存在明确的自杀计划和/或自杀企图的患者; d) 研究者认为的其他可能影响研究实施(如色盲、听力障碍、智力障碍等)的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
a) Current or past history of schizophrenia, bipolar disorder, etc. (anxiety disorder spectrum is not excluded); b) History of neurological diseases or major physical illnesses (such as thyroid disease, lupus erythematosus, diabetes, lung, liver or kidney damage, infections, major trauma, glaucoma, etc.); or history of substance use disorders; c) Patients with clear current suicide plans and/or suicide attempts; d) Other conditions that researchers believe may affect the implementation of the study (such as color blindness, hearing impairment, intellectual disability, etc.). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-09-05 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-27 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由一名独立于研究者和受试者的操作人员使用计算机软件随机生成数字序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
An operator independent of the researchers and participants uses computer software to randomly generate a sequence of numbers |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲:受试者和研究者均不知道受试者接受的是哪种干预方式。 |
|
Blinding: |
Double-blind: Both the participants and the researchers are unaware of which intervention the participants are receiving. |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究的原始数据将在研究结果发表后的6个月内公开。有需要的研究者可以通过联系研究负责人申请获取数据。研究者需向研究负责人提出申请,并说明数据使用的目的和计划。在申请获批后,数据将以电子形式提供给申请者,但需确保数据的使用符合伦理要求,并保护受试者的隐私 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data of this study will be made available to the public within 6 months after the publication of the study results. Researchers who need the data may apply to the study principal investigator for access. The applicant must submit a request to the principal investigator, detailing the purpose and plan for data usage. Once the application is approved, the data will be provided to the applicant in electronic form. However, the use of the data must comply with ethical requirements and ensure the protection of participants' privacy. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF和EDC并行 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and EDC in parallel |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |